To the full analysis
C4 Therapeutics stock: growth
CCCCC4 Therapeutics reported $35.95M in revenue for fiscal 2025, up 1% on the prior year, up 1.6% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
9.2%
per year from 2018 to 2025, per share −14.6%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2018 | |
|---|---|---|
| Revenue | 1.6% | 9.2% |
| Revenue per share | −10.9% | −14.6% |
| Earnings | no data | no data |
| Earnings per share | no data | no data |
| Free cash flow | no data | no data |
| Free cash flow per share | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2018 | $19.36M | −$15.71M | −$19.67M |
| 2019 | $21.38M | −$34.1M | $54.27M |
| 2020 | $33.2M | −$66.33M | −$67.9M |
| 2021 | $45.79M | −$83.89M | −$88.24M |
| 2022 | $31.1M | −$128.18M | −$111.44M |
| 2023 | $20.76M | −$132.49M | −$108.55M |
| 2024 | $35.58M | −$105.32M | −$65.34M |
| 2025 | $35.95M | −$104.99M | −$99.3M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Sep 2021)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.